Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867230 | 1.00 | CYP1A2 (0.61) | CYP1A2HPGDHDAC3HDAC1HDAC2 | |
| SCHEMBL29435026 | 0.89 | HDAC3 (0.58) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL222876 | 0.89 | HDAC3 (0.58) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL29029431 | 0.88 | HDAC3 (0.56) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL607975 | 0.88 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL22018723 | 0.88 | HDAC3 (0.57) | CYP1A2HPGDHDAC3HDAC1HDAC2 | |
| SCHEMBL15789054 | 0.88 | RAB9A (0.61) | CYP1A2HPGDHDAC3HDAC1HDAC2 | |
| SCHEMBL7439456 | 0.88 | HDAC3 (0.57) | CYP1A2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL7439461 | 0.86 | HDAC3 (0.56) | CYP1A2HPGDHDAC3HDAC1HDAC2 | |
| SCHEMBL9646358 | 0.86 | PDK1 (0.59) | CYP1A2HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2023-09-26 | — | — | US | disclosed |
| CN-116715625-A | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-111601790-B | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2021021761-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| EP-3749646-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | Fujian Haixi Pharmaceuticals Co., Ltd (CN) | 2020-12-16 | — | — | EP | disclosed |
| CN-111601790-A | Heteroaryl compounds as protein kinase inhibitors | 福建海西新药创制有限公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2019174601-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019174601-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2019-09-19 | — | — | WO | disclosed |
| EP-3154982-B1 | COMPOUNDS COMPRISING 1,1',2,5'-TETRAHYDROSPIRO[INDOLE-3,2'-PYRROLE]-2,5'-DIONE SYSTEM AS INHIBITORS P53-MDM2 PROTEIN-PROTEIN INTERACTION | ADAMED SP ZOO (PL) | 2018-05-02 | — | — | EP | disclosed |
| US-20170129903-A1 | COMPOUNDS COMPRISING 1,1a,2,5a-TETRAHYDROSPIRO[INDOLE-3,2a-PYRROLE]-2,5a-DIONE SYSTEM AS INHIBITORS P53-MDM2 PROTEIN-PROTEIN INTERACTION | ADAMED SP. Z O.O. (PL) | 2017-05-11 | — | — | US | disclosed |
| WO-2015189799-A1 | COMPOUNDS COMPRISING 1,1',2,5'-TETRAHYDROSPIRO[INDOLE-3,2'-PYRROLE]-2,5'-DIONE SYSTEM AS INHIBITORS P53-MDM2 PROTEIN-PROTEIN INTERACTION | ADAMED SP. Z O.O. (PL) | 2015-12-17 | — | — | WO | disclosed |
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20050020566-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443047-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-08-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020566-A1 | Novel carbapenem compounds | HPN, PRSS1, BPGM | CYP1A2 4121/4885HPGD 669/4885HDAC3 913/4885 |
| US-20240228482-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | TP53, CASP3, BAX | CYP1A2 1412/4885HPGD 401/4885HDAC3 96/4885 |
| US-20170129903-A1 | COMPOUNDS COMPRISING 1,1a,2,5a-TETRAHYDROSPIRO[INDOLE-3,2a-PYRROLE]-2,5a-DIONE SYSTEM AS INHIBITORS P53-MDM2 PROTEIN-PROTEIN INTERACTION | MDM2, TP53, TP53BP1 | CYP1A2 290/4885HPGD 167/4885HDAC3 2577/4885 |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | CYP1A2 3595/4885HPGD 4340/4885HDAC3 2543/4885 |
| US-11767296-B2 | Heteroaryl compounds as kinase inhibitor | RET, ERBB2, ABL1 | CYP1A2 1556/4885HPGD 4557/4885HDAC3 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.